



SK Life Science, Inc. to Host “Illuminating the Path to Added Seizure Reduction” Symposium at the 2025 American Epilepsy Society Annual Meeting

Expert panel to explore evolving approaches and real-world insights in epilepsy treatment

Paramus, N.J. – October 24, 2025 – [SK Life Science, Inc.](#), a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., today announced it will host an educational symposium led by world-renowned epileptologists during the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia.

The symposium, “Illuminating the Path to Added Seizure Reduction,” will take place on Friday, December 5, 2025, at the Omni Atlanta Hotel at Centennial Park (Grand Ballroom D). Doors open at 6:00 PM, and the presentation begins at 6:30 PM.

Featured faculty include:

- **Pavel Klein, MB BChir, FAAN, FAES**, Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland
- **Danielle Becker, MD, MS, FAES**, The Ohio State University Wexner Medical Center, Columbus, Ohio
- **Raman Sankar, MD, PhD, FAAN, FAES**, David Geffen School of Medicine at UCLA, Los Angeles, California
- **John M. Stern, MA, MD, FAES, FANA, FAAN**, David Geffen School of Medicine at UCLA, Los Angeles, California

This interactive session will highlight the evolving landscape of epilepsy treatment, focusing on the critical role of third-generation antiseizure medications (ASMs) and the continued pursuit of seizure freedom for patients living with epilepsy.

The symposium will cover three key objectives:

- Understanding how treatment approaches for epilepsy have evolved, with an emphasis on the role of third-generation ASMs.
- Examining real-world patient cases to understand how treatment decisions affect outcomes.
- Exploring shifts in clinician perspectives and evaluating treatment options that offer potential for achieving seizure freedom.

“Education and collaboration are essential to advancing the care of people living with epilepsy,” said Matt Linkewich, Chief Commercial Officer at SK Life Science. “Through programs like this

symposium, we aim to provide clinicians with the latest clinical insights and real-world data to help them make informed treatment decisions, ultimately supporting our shared goal of helping more patients achieve seizure freedom.”

Interested attendees can pre-register at <https://aes2025.scimedregister.com/>.

About SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd.

SK Life Science, Inc., with headquarters in Paramus, New Jersey, is a U.S. subsidiary of **SK Biopharmaceuticals Co., Ltd.**, a pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with eight compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content screening, computer-aided drug design, and combinatorial chemistry, the companies drive R&D efforts in biology/discovery, medicinal chemistry, pharmacology, and clinical development. For more information, visit www.SKLifeScienceInc.com.

SK Biopharmaceuticals Co., Ltd. is part of **SK Group**, South Korea’s second-largest conglomerate. SK Group is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals and digital business. Based in Seoul, SK invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions. SK companies combined have \$151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME's 100 Most Influential Companies of 2023. **SK Inc.**, the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information about SK Inc., visit <https://sk-inc.com/en/main/mainpage.aspx>. For more information about SK Biopharmaceuticals, visit www.skbp.com/eng.

Media Contact:

Dina Albanese
Corporate Communication
media@sklsi.com

###